The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes
To generate a combination of serum zinc (Zn) and prostate-specific antigen (PSA) in an attempt to provide better prediction of prostate biopsy outcomes with Zn/PSA ratios. Diagnostic performances of PSA and Zn/PSA were investigated using receiver operating characteristic and the area under the curve...
Gespeichert in:
| Veröffentlicht in: | Biomarkers in medicine 2019-02, Vol.13 (2), p.59-68 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 68 |
|---|---|
| container_issue | 2 |
| container_start_page | 59 |
| container_title | Biomarkers in medicine |
| container_volume | 13 |
| creator | Temiz, Mustafa Zafer Cakir, Omer Onur Aykan, Serdar Kucuk, Suat Hayri Tiryakioglu, Necip Ozan Bilek, Gunal Tunali, Nagehan Ersoy Kandirali, Engin Semercioz, Atilla |
| description | To generate a combination of serum zinc (Zn) and prostate-specific antigen (PSA) in an attempt to provide better prediction of prostate biopsy outcomes with Zn/PSA ratios.
Diagnostic performances of PSA and Zn/PSA were investigated using receiver operating characteristic and the area under the curve analysis and McNemar test in 480 men. Decision curve analysis was also used to determine the net clinical benefits of the two parameters.
The receiver operating characteristic-area under the curve analysis established a similar diagnostic performance for both parameters. Although Zn/PSA had a higher diagnostic sensitivity, PSA was superior in terms of specificity and net clinical benefits.
Zn/PSA has no substantial superiority in the prediction of prostate biopsy outcomes. |
| doi_str_mv | 10.2217/bmm-2018-0260 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179490553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216505785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-1959e425afcad5b11f0ea15ec354227f9b72c0e30f8233838d013571728da1323</originalsourceid><addsrcrecordid>eNp1kTtPHDEURi0UFDaQkjayREMzwY_1eKaMEI9ISGmgtjyea_Bmx574USy_Ho-WpUBKZVs-Orr3-xA6p-QnY1ReDdPUMEK7hrCWHKEVlYI1hEv65ePe8hP0LaUNIULKln1FJ5y0knHSr1B5fAFcEuBgcYJYJvzqvME54DmGlHWGJs1gnHUGa5_dM3gcdXYB64Q1HlyYdPwLETuPc1XNEUZn6r9fjAfHws1ph0PJJkyQztCx1dsE39_PU_R0e_N4fd88_Ln7ff3roTF1gdzQXvSwZkJbo0cxUGoJaCrAcLFmTNp-kMwQ4MR2jPOOdyOhXEgqWTdqyhk_RZd7bx3kX4GU1eSSge1WewglqRpgv-6JELyiF5_QTSjR1-lUzbkVNbtOVKrZU6ZuliJYNUdXE9gpShZOqtqHWvpQSx-V__FuLcME4wd9KKAC_R6wJZcIyTjwBtT-NS1ZOg__kb8B4zSZbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216505785</pqid></control><display><type>article</type><title>The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes</title><source>MEDLINE</source><source>PubMed Central</source><creator>Temiz, Mustafa Zafer ; Cakir, Omer Onur ; Aykan, Serdar ; Kucuk, Suat Hayri ; Tiryakioglu, Necip Ozan ; Bilek, Gunal ; Tunali, Nagehan Ersoy ; Kandirali, Engin ; Semercioz, Atilla</creator><creatorcontrib>Temiz, Mustafa Zafer ; Cakir, Omer Onur ; Aykan, Serdar ; Kucuk, Suat Hayri ; Tiryakioglu, Necip Ozan ; Bilek, Gunal ; Tunali, Nagehan Ersoy ; Kandirali, Engin ; Semercioz, Atilla</creatorcontrib><description>To generate a combination of serum zinc (Zn) and prostate-specific antigen (PSA) in an attempt to provide better prediction of prostate biopsy outcomes with Zn/PSA ratios.
Diagnostic performances of PSA and Zn/PSA were investigated using receiver operating characteristic and the area under the curve analysis and McNemar test in 480 men. Decision curve analysis was also used to determine the net clinical benefits of the two parameters.
The receiver operating characteristic-area under the curve analysis established a similar diagnostic performance for both parameters. Although Zn/PSA had a higher diagnostic sensitivity, PSA was superior in terms of specificity and net clinical benefits.
Zn/PSA has no substantial superiority in the prediction of prostate biopsy outcomes.</description><identifier>ISSN: 1752-0363</identifier><identifier>EISSN: 1752-0371</identifier><identifier>DOI: 10.2217/bmm-2018-0260</identifier><identifier>PMID: 30672309</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Aged ; Antigens ; Area Under Curve ; Biomarkers ; Biomarkers, Tumor - blood ; Biopsy ; Decision Support Techniques ; Follow-Up Studies ; Humans ; Immunoassay ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Prostate ; Prostate cancer ; Prostate-specific antigen ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - surgery ; Software ; Studies ; Surveillance ; Systematic review ; Trace elements ; Ultrasonic imaging ; Urology ; zinc ; Zinc - blood</subject><ispartof>Biomarkers in medicine, 2019-02, Vol.13 (2), p.59-68</ispartof><rights>2019 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Feb 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-1959e425afcad5b11f0ea15ec354227f9b72c0e30f8233838d013571728da1323</citedby><cites>FETCH-LOGICAL-c371t-1959e425afcad5b11f0ea15ec354227f9b72c0e30f8233838d013571728da1323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30672309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Temiz, Mustafa Zafer</creatorcontrib><creatorcontrib>Cakir, Omer Onur</creatorcontrib><creatorcontrib>Aykan, Serdar</creatorcontrib><creatorcontrib>Kucuk, Suat Hayri</creatorcontrib><creatorcontrib>Tiryakioglu, Necip Ozan</creatorcontrib><creatorcontrib>Bilek, Gunal</creatorcontrib><creatorcontrib>Tunali, Nagehan Ersoy</creatorcontrib><creatorcontrib>Kandirali, Engin</creatorcontrib><creatorcontrib>Semercioz, Atilla</creatorcontrib><title>The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes</title><title>Biomarkers in medicine</title><addtitle>Biomark Med</addtitle><description>To generate a combination of serum zinc (Zn) and prostate-specific antigen (PSA) in an attempt to provide better prediction of prostate biopsy outcomes with Zn/PSA ratios.
Diagnostic performances of PSA and Zn/PSA were investigated using receiver operating characteristic and the area under the curve analysis and McNemar test in 480 men. Decision curve analysis was also used to determine the net clinical benefits of the two parameters.
The receiver operating characteristic-area under the curve analysis established a similar diagnostic performance for both parameters. Although Zn/PSA had a higher diagnostic sensitivity, PSA was superior in terms of specificity and net clinical benefits.
Zn/PSA has no substantial superiority in the prediction of prostate biopsy outcomes.</description><subject>Aged</subject><subject>Antigens</subject><subject>Area Under Curve</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biopsy</subject><subject>Decision Support Techniques</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoassay</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Prostate</subject><subject>Prostate cancer</subject><subject>Prostate-specific antigen</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Software</subject><subject>Studies</subject><subject>Surveillance</subject><subject>Systematic review</subject><subject>Trace elements</subject><subject>Ultrasonic imaging</subject><subject>Urology</subject><subject>zinc</subject><subject>Zinc - blood</subject><issn>1752-0363</issn><issn>1752-0371</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kTtPHDEURi0UFDaQkjayREMzwY_1eKaMEI9ISGmgtjyea_Bmx574USy_Ho-WpUBKZVs-Orr3-xA6p-QnY1ReDdPUMEK7hrCWHKEVlYI1hEv65ePe8hP0LaUNIULKln1FJ5y0knHSr1B5fAFcEuBgcYJYJvzqvME54DmGlHWGJs1gnHUGa5_dM3gcdXYB64Q1HlyYdPwLETuPc1XNEUZn6r9fjAfHws1ph0PJJkyQztCx1dsE39_PU_R0e_N4fd88_Ln7ff3roTF1gdzQXvSwZkJbo0cxUGoJaCrAcLFmTNp-kMwQ4MR2jPOOdyOhXEgqWTdqyhk_RZd7bx3kX4GU1eSSge1WewglqRpgv-6JELyiF5_QTSjR1-lUzbkVNbtOVKrZU6ZuliJYNUdXE9gpShZOqtqHWvpQSx-V__FuLcME4wd9KKAC_R6wJZcIyTjwBtT-NS1ZOg__kb8B4zSZbA</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Temiz, Mustafa Zafer</creator><creator>Cakir, Omer Onur</creator><creator>Aykan, Serdar</creator><creator>Kucuk, Suat Hayri</creator><creator>Tiryakioglu, Necip Ozan</creator><creator>Bilek, Gunal</creator><creator>Tunali, Nagehan Ersoy</creator><creator>Kandirali, Engin</creator><creator>Semercioz, Atilla</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190201</creationdate><title>The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes</title><author>Temiz, Mustafa Zafer ; Cakir, Omer Onur ; Aykan, Serdar ; Kucuk, Suat Hayri ; Tiryakioglu, Necip Ozan ; Bilek, Gunal ; Tunali, Nagehan Ersoy ; Kandirali, Engin ; Semercioz, Atilla</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-1959e425afcad5b11f0ea15ec354227f9b72c0e30f8233838d013571728da1323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Antigens</topic><topic>Area Under Curve</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biopsy</topic><topic>Decision Support Techniques</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoassay</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Prostate</topic><topic>Prostate cancer</topic><topic>Prostate-specific antigen</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Software</topic><topic>Studies</topic><topic>Surveillance</topic><topic>Systematic review</topic><topic>Trace elements</topic><topic>Ultrasonic imaging</topic><topic>Urology</topic><topic>zinc</topic><topic>Zinc - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Temiz, Mustafa Zafer</creatorcontrib><creatorcontrib>Cakir, Omer Onur</creatorcontrib><creatorcontrib>Aykan, Serdar</creatorcontrib><creatorcontrib>Kucuk, Suat Hayri</creatorcontrib><creatorcontrib>Tiryakioglu, Necip Ozan</creatorcontrib><creatorcontrib>Bilek, Gunal</creatorcontrib><creatorcontrib>Tunali, Nagehan Ersoy</creatorcontrib><creatorcontrib>Kandirali, Engin</creatorcontrib><creatorcontrib>Semercioz, Atilla</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Biomarkers in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Temiz, Mustafa Zafer</au><au>Cakir, Omer Onur</au><au>Aykan, Serdar</au><au>Kucuk, Suat Hayri</au><au>Tiryakioglu, Necip Ozan</au><au>Bilek, Gunal</au><au>Tunali, Nagehan Ersoy</au><au>Kandirali, Engin</au><au>Semercioz, Atilla</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes</atitle><jtitle>Biomarkers in medicine</jtitle><addtitle>Biomark Med</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>13</volume><issue>2</issue><spage>59</spage><epage>68</epage><pages>59-68</pages><issn>1752-0363</issn><eissn>1752-0371</eissn><abstract>To generate a combination of serum zinc (Zn) and prostate-specific antigen (PSA) in an attempt to provide better prediction of prostate biopsy outcomes with Zn/PSA ratios.
Diagnostic performances of PSA and Zn/PSA were investigated using receiver operating characteristic and the area under the curve analysis and McNemar test in 480 men. Decision curve analysis was also used to determine the net clinical benefits of the two parameters.
The receiver operating characteristic-area under the curve analysis established a similar diagnostic performance for both parameters. Although Zn/PSA had a higher diagnostic sensitivity, PSA was superior in terms of specificity and net clinical benefits.
Zn/PSA has no substantial superiority in the prediction of prostate biopsy outcomes.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>30672309</pmid><doi>10.2217/bmm-2018-0260</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1752-0363 |
| ispartof | Biomarkers in medicine, 2019-02, Vol.13 (2), p.59-68 |
| issn | 1752-0363 1752-0371 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179490553 |
| source | MEDLINE; PubMed Central |
| subjects | Aged Antigens Area Under Curve Biomarkers Biomarkers, Tumor - blood Biopsy Decision Support Techniques Follow-Up Studies Humans Immunoassay Male Middle Aged Prognosis Prospective Studies Prostate Prostate cancer Prostate-specific antigen Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - surgery Software Studies Surveillance Systematic review Trace elements Ultrasonic imaging Urology zinc Zinc - blood |
| title | The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A06%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20serum%20zinc%20to%20prostate-specific%20antigen%20ratio%20as%20a%20biomarker%20in%20the%20prediction%20of%20prostate%20biopsy%20outcomes&rft.jtitle=Biomarkers%20in%20medicine&rft.au=Temiz,%20Mustafa%20Zafer&rft.date=2019-02-01&rft.volume=13&rft.issue=2&rft.spage=59&rft.epage=68&rft.pages=59-68&rft.issn=1752-0363&rft.eissn=1752-0371&rft_id=info:doi/10.2217/bmm-2018-0260&rft_dat=%3Cproquest_cross%3E2216505785%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216505785&rft_id=info:pmid/30672309&rfr_iscdi=true |